We are pleased to announce that we are now accepting phase III oncology Clinical Trials of Investigational Medicinal Products (CTIMPs) for review through Pharmacy Assurance in England and Wales from Monday 18 March 2019. In this second phase of roll-out we will continue to accept oncology phase I, I/II, II and II/III CTIMPs.
Detailed submission guidance can be found on IRAS. We encourage applicants to submit any eligible studies.
We are also welcoming more applications from those with the appropriate expertise to become Pharmacy Assurance registered reviewers. We are particularly interested in receiving applications from radiopharmacists or radiopharmaceutical scientists. Further information on how to apply is available on our website page.